Autolus Therapeutics (AUTL) Common Equity (2017 - 2026)

Autolus Therapeutics (AUTL) has 9 years of Common Equity data on file, last reported at $178.1 million in Q4 2025.

• Quarterly Common Equity fell 58.32% year-over-year to $178.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $178.1 million (down 58.32% YoY) and the FY2025 annual result came in at $178.1 million, down 58.32% from the prior year.
• Common Equity eased to $178.1 million in Q4 2025, from $265.5 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $582.0 million in Q1 2024 to a low of $111.5 million in Q4 2023.
• A 5-year average of $302.5 million and a median of $277.4 million in 2021 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2023 — Common Equity tumbled 62.68% — and 2024, when it surged 283.34%.
• Tracing AUTL's Common Equity over 5 years: stood at $313.3 million in 2021, then decreased by 4.67% to $298.7 million in 2022, then plunged by 62.68% to $111.5 million in 2023, then surged by 283.34% to $427.3 million in 2024, then sank by 58.32% to $178.1 million in 2025.
• The last three Common Equity figures came in at $178.1 million (Q4 2025), $265.5 million (Q3 2025), and $346.5 million (Q2 2025), per Business Quant data.